作者
George N Ioannou, Lauren A Beste, Pamela K Green, Amit G Singal, Elliot B Tapper, Akbar K Waljee, Richard K Sterling, Jordan J Feld, David E Kaplan, Tamar H Taddei, Kristin Berry
发表日期
2019/11/1
期刊
Gastroenterology
卷号
157
期号
5
页码范围
1264-1278. e4
出版商
WB Saunders
简介
Background & Aims
It is unclear if hepatocellular carcinoma (HCC) risk declines over time after hepatitis C virus (HCV) eradication. We analyzed changes in HCC annual incidence over time following HCV eradication and identified dynamic markers of HCC risk.
Methods
We identified 48,135 patients who initiated HCV antiviral treatment from 2000 through 2015 and achieved a sustained virologic response (SVR) in the Veterans Health Administration (29,033 treated with direct-acting antiviral [DAA] agents and 19,102 treated with interferon-based regimens). Patients were followed after treatment until February 14, 2019 (average 5.4 years), during which 1509 incident HCCs were identified.
Results
Among patients with cirrhosis before treatment with DAAs (n = 9784), those with pre-SVR fibrosis-4 (FIB-4) scores ≥3.25 had a higher annual incidence of HCC (3.66%/year) than those with FIB-4 scores <3.25 (1.16%/year …
学术搜索中的文章
GN Ioannou, LA Beste, PK Green, AG Singal… - Gastroenterology, 2019